Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: Wright Reports
Provider: New Constructs, LLC
Provider: Stock Traders Daily

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

United Therapeutics Corp Updates FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates

Tuesday, 29 Oct 2013 06:00am EDT 

United Therapeutics Corp updated its fiscal 2013 revenue guidance for the Company's three commercial products (Remodulin , Tyvaso and Adcirca) and the Company expect to exceed the upper end of the previous guidance range of $1.05 billion. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $1.08 billion for fiscal 2013. 

Company Quote

0.28 +0.22%
1:13pm EDT